Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study

• Type of Material: Article
• Authors: Jesus Berdeja, Sarah Cannon Research Institute; Sundar Jagannath, Mt Sinai Hospital; Jeffrey Zonder, Wayne State University; Ashraf Badros, University of Maryland; Jonathan Kaufman, Emory University; Robert Manges, Investigative Clinical Research of Indiana; Manish Gupta, Bristol-Myers Squibb; Amol Tendolkar, Bristol-Myers Squibb; Mark Lynch, Bristol-Myers Squibb; Eric Bleickardt, Bristol-Myers Squibb; Prashni Paliwal, Bristol-Myers Squibb; Ravi Vij, Washington University
• Language: English
• Date: 2016-03-01
• Publisher: Elsevier Inc.
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2021 Elsevier Inc
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.clml.2015.12.007
• Title of Journal or Parent Work: Clinical Lymphoma Myeloma and Leukemia
• Volume: 16
• Issue: 3
• Start Page: 129
• End Page: 138
• Grant/Funding Information: The present analysis was supported by research funding from Bristol-Myers Squibb.
• Keywords: Creatinine clearance; Life Sciences & Biomedicine; Glomerular filtration rate; End-stage renal disease; Oncology; MANAGEMENT; Science & Technology; CS1; SLAMF7; FAILURE; DOSE DEXAMETHASONE; Hematology; PLUS DEXAMETHASONE; EFFICACY; IMPACT; OPEN-LABEL; Monoclonal antibody; BORTEZOMIB; THERAPY
• Research Categories: Health Sciences, Oncology

Abstract

Renal impairment is associated with a poor prognosis in patients with multiple myeloma (MM), and more treatment options are needed. The pharmacokinetics of elotuzumab, a humanized IgG1 monoclonal antibody, combined with lenalidomide and dexamethasone, is not significantly different between patients with MM with and without renal impairment, suggesting that elotuzumab might be administered without dose adjustment for renal function.